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a  b  s  t  r  a  c  t
Aim: The feasibility of using 230 MeV proton cyclotrons in proton therapy centers as a spal-
lation neutron source for Boron Neutron Capture Therapy (BNCT) was investigated.
Background: BNCT is based on the neutron irradiation of a 10B-containing compound located
selectively in tumor cells. Among various types of neutron generators, the spallation neutron
source is a unique way to generate high-energy and high-flux neutrons.
Materials and Methods: Neutron beam was generated by a proton accelerator via spallation
reactions and then the produced neutron beam was shaped to be appropriate for BNCT.
The  proposed Beam Shaping Assembly (BSA) consists of different moderators, a reflector,
a  collimator, as well as thermal and gamma filters. In addition, the simulated Snyder head
phantom was utilized to evaluate the dose distribution in tumor and normal tissue due to
the  irradiation by the designed beam. MCNPX2.6 Monte Carlo code was used to optimize
BSA as well as evaluate dose evaluation.
Results: A BSA was designed. With the BSA configuration and a beam current of 104 nA,
epithermal neutron flux of 3.94 × 106 [n/cm2] can be achieved, which is very low. Provided
that we use the beam current of 5.75 A, epithermal neutron flux of 2.18 × 108 [n/cm2]  can
be  obtained and the maximum dose of 38.2 Gy-eq can be delivered to tumor tissue at 1.4 cmfrom  the phantom surface.
Conclusions: Results for 230 MeV protons show that with proposed BSA, proton beam current
about 5.75 A is required for this purpose.
© 2019 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.
in brain, skin, lung, liver, prostate, head and neck tumors1.  IntroductionBoron Neutron Capture Therapy (BNCT) is a binary cancer
therapy modality which has attracted extensive interest in
recent decades due to its potential for selective cell killing.1
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1507-1367/© 2019 Greater Poland Cancer Centre. Published by Elsevier BNCT has led to many  important therapeutic applications
in diverse areas of cancer treatment with notable examples
2–4for which conventional therapies, like chemotherapy, surgery,
and radiotherapy are not completely successful. The idea of
BNCT dates back to 1936 when Locher initially recognized the

















































reports of practical oncology and 
herapeutic potential of Boron Neutron Capture reaction, i.e.
0B(n,)7Li, which was four years after the discovery of neutron
y Chadwick.5
BNCT has two key steps. In the first step, a boron-
ontaining compound, such as Boron Phenylalanine (BPA) or
orocaptate Sodium (BSH), is administered to the patient such
hat they it is deposited on the tumor more  than normal tis-
ue. In the next step, tumor area is subjected to the neutron
rradiation.6
During neutron irradiation, 10B promptly disintegrates into
wo high linear-energy-transfer (LET) particles, an  particle
nd 7Li nucleus, via the 10B(n,)7Li reaction (1)-(2)7,8:
0B + nth→7Li(0.84 MeV) + ˛(1.47 MeV) + (0.48 MeV)(93.7%)
(1)
0B + nth→7Li(1.01 MeV) + ˛(1.78 MeV)(6.3%) (2)
The high-LET radiation released in the tumor cells by
he interaction of 10B with thermal neutrons would be suffi-
ient to kill or sterilize the tumor cells; and the short-range
<10 m ∼ cell diameter) of the particles produced by the
eutron capture reaction could limit the damage to the cells
ontaining 10B.
Most used neutron sources for BNCT are reactors, so the
umber of BNCT centers are limited. Since the accelerator-
ased BNCT (AB-BNCT) has much lower costs than the
eactor-based BNCT (RB-BNCT), the AB-BNCT is being estab-
ished worldwide as the future modality to start the era
f in-hospital facilities. For this reason, the neutron pro-
uction based on spallation reactions using accelerators in
roton therapy centers was evaluated in this research. In
rder to provide an appropriate neutron beam, a Beam Shap-
ng Assembly (BSA) should be designed based on the neutron
ource specifications. The aim of the present work is to
erform a feasibility study on the use of 230 MeV  proton
yclotron in proton therapy centers as neutron source for
NCT. For this purpose, the proton accelerator (104 nA9) in
oston proton therapy center in the United States of Amer-
ca was considered. Simulations were performed by using
he Monte Carlo code MCNPX2.6, with the Los Alamos LA150
ata library (E ≤ 150 MeV) and physical models embedded
n the code (E ≥ 150 MeV),10 for the design of the tar-
et and BSA and considering the dose distribution in the
epth of the head phantom. In this study, neutrons hav-
ng energies below 1 eV, between 1 eV and 10 keV and above
0 keV are referred to as thermal, epithermal and fast neu-
rons, respectively. Usually, cancer cells are located deeper
nside the human body, and in these cases, it is generally
ccepted that epithermal neutron beams of energy ∼10 keV
re optimal.11
.  Aimhis work aims to explore the application feasibility of
30 MeV  proton cyclotrons in proton therapy centers to be
sed as a spallation neutron source for BNCT.therapy 2 4 ( 2 0 1 9 ) 644–653 645
3.  Materials  and  methods
3.1.  Neutron  and  photon  transport  calculations
In this study, neutron and photon transport simulations from
the neutron source to the head phantom were performed
using Monte Carlo MCNPX2.6 code in order to optimize the
spallation target, the BSA design and compute the dose dis-
tribution in a head phantom for a BNCT facility. Variance
reduction techniques, such as geometry splitting with Russian
roulette have been utilized to decrease the simulation time.
The Los Alamos LA150 data library (E ≤ 150 MeV) and physical
models embedded in the code (E ≥ 150 MeV) have been used
in the simulations.
3.2.  Spallation  target
Generally, heavy nuclei are used for spallation targets because
the neutron production in the spallation process is the most
efficient for large nuclei.12 Tantalum (Ta), Tungsten (W), Mer-
cury (Hg), Lead (Pb), Lead-Bismuth eutectic (LBE) can be used as
a target material, but the use of non-actinide materials, such
as Ta, W,  and Pb, became the unique solution suggested to be
used as solid targets at beam power levels far below 1 MW and
the liquid targets at higher power.12 Neutron yield is one of
the most significant factors in the selection of target material.
Heat transfer characteristics and thermal resistance are the
other important factors for choosing the target material.13 In
this study, Ta, W,  Pb, LBE and Bi were tested as spallation target
materials and simulations for materials with different dimen-
sions were performed to obtain the best material in optimum
dimension as well as appropriate angle of spallation target
relative to the proton beam direction. A comparison between
the parameters used in this study and some existing spallation
neutron sources are listed in Table 1.
3.3.  Design  and  optimization  of  BSA
A BSA facility should be designed with the intention of mod-
erating high-energy neutrons from the spallation reactions
to lower energies as well as eliminate fast and thermal neu-
trons and gamma  contaminations in order to satisfy the
International Atomic Energy Agency (IAEA) recommendation
(Table 2).11 Every BSA facility consists of several layers of
different materials, including reflector, moderator, collimator
thermal neutron filter, and gamma filter.
The moderator should have a high fast neutron scatter-
ing cross-section (
∑
s,fast→epi) and low epithermal neutron







r→epi parameter is as high as
possible. Moreover, the moderator should have a low fast neu-
tron absorption cross-section because fast neutrons will be
removed from the spectrum and cannot contribute to the
lower energy regions anymore. In addition, gamma contami-
nation due to neutron interactions should be as low as possible
in the BSA.7
A reflector decreases the neutron leakage and can further
improve the quality of the beam.11
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Table 1 – Main parameters of some existing spallation neutron sources.
Accelerator Proton kinetic energy Beam current Target material
SNS Oak Ridge14 1.0 GeV 1.4 mA Hg
KENS Japan15 500 MeV 10 A W (Ta Clad)
LNSC Los Alamos16 800 MeV 80 A W
ISIS Oxford17 800 MeV 200 A W (Ta Clad)
SINQ Villigen18 590 MeV 2.3 mA Pb Rods (in Zircaloy Tubes)
IPNS Argonne USA19 450 MeV 15 A U238
Mass General Hospital,
Boston, MA (which was
evaluated in this study)9
230 MeV 104 nA W
Table 2 – Recommended values in the beam exit
window11 (∅ symbolizes the flux and Ḋ symbolizes the
dose rate).
BNCT in-air parameters Recommended value
∅epithermal [n/cm2s]  ∼1 × 109
∅epithermal/∅fast >20
∅epithermal/∅thermal >100
Ḋfast/∅epithermal [Gycm2/n] <2 × 10−13
Ḋ /∅epithermal [Gycm2/n] <2 × 10−13
J/∅a >0.7
Fast energy group ∅fast E>10 keV
Epithermal energy group ∅epi 1 eV ≤ E ≤ 10 keV
Thermal energy group ∅th E<1 eV
a The ratio between the total neutron current and the total neutron
flux.
Table 3 – The phantom materials and dimensions.6
Snyder head phantom
Material Water and Liquid-B
Geometry Ellipsoidal
Diameter (cm) 16
(x/6.8)2+(y/9.8)2+(z/8.3)2 = 1(skull–skinboundary) (5)
(x/7.3)2+(y/10.3)2+(z/8.8)2 = 1(skull–airboundary) (6)The beam collimator should be designed in order to maxi-
mize the dose delivered to the tumor and minimize the dose
delivered to the rest of the body. In fact, collimators can be
used to improve the ratio of current to flux of the final incident
beam.20
As mentioned before, in order to obtain an epithermal neu-
tron beam with high quality, the undesired gamma  rays as
well as thermal and fast neutrons are removed using appropri-
ate filters. Several sets of materials have been considered and
the neutron spectra have been investigated based on energy
and intensity. In this study, materials including Iron (Fe), Alu-
minum (Al) and Magnesium Fluorine (MgF2) were tested as
the moderators. Iron has high inelastic scattering cross sec-
tion above 860 keV, a window at 20 keV and it decreases the
fast neutron flux below the 100 keV.21 Magnesium fluorine also
presents a good performance in terms of neutrons accumu-
lation inside the epithermal energy range; magnesium and
fluorine have strong resonance structures in elastic scattering
cross section for fast neutrons and also these two elements
have relatively small mass numbers. Aluminum has a low
enough first excited state to make useful inelastic scatter-
ing, and it is ideal to decrease the high neutron flux in the
range of >843.8 keV. The size of the moderators was optimized
by parametric studies from the perspective of the dose depth
distribution, the absolute dose to tumor tissue and the thera-
peutic time.
Beam quality is evaluated by parameters recommended by
IAEA for BNCT (Table 2).Length (cm) 20
PMMA wall thickness (mm) 2
3.4.  Dose  evaluation
Absorbed dose delivered to the normal tissue and tumor dur-
ing BNCT result from possible reactions. Four major dose
components in BNCT are the dose from the 10B(n,)7Li cap-
ture reaction, DB; the dose due to 14N(n,p)14C reaction, DN; the
neutron dose from fast neutrons, DF; and the  ray dose from 
ray contamination in the neutron beam and neutron capture
reaction, D.22
The weighted dose commonly known as total biologically
weighted dose (DT) for the patient is defined as a sum of four
physical dose components each multiplied by a specific bio-
logical weighting factor according to Eq. (3)20:
DT= CB.wB.DB+wN.DN+wF.DF+w.D[Gy-equivalent] (3)
CB is the boron concentration in the tissue in units of ppm.
Boron concentration in the tumor must be higher than boron
concentration in the normal brain. The weighting factors wN
and wF are taken as 3.2, and w is considered to be 1.0 in the
tumor and normal tissue. wB is assumed to be 1.3 and 3.8 in
the normal tissue and the tumor, respectively. Flux to dose
conversion factors were utilized to calculate each dose com-
ponent. The weighting factors were taken from values used in
BNL’s protocol.23 The computational head phantom model is
Snyder, which consists of the skin, the skull, the head volume
and the tumor.
In this paper, the Snyder head phantom with anatomical
structures (skin, skull, brain and possibly tumor) was utilized
to test the important aspects of the treatment planning codes,
such as dose volume calculation. The phantom material and
dimensions are described in Tables 3 and 4.24 The used head
phantom ellipsoidal geometry is described in Eqs. (4)–(6).25
(x/6)2+(y/9)2+((z−1)/6.5)2 = 1(brain–skullboundary) (4)
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Fig. 1 – (A) Neutron yield of spallation targets in different radii. (B) Number of neutrons on the surface in different radii.
Table 4 – The Snyder phantom material, according to




Density (g/cm3) 1.040 1.090 1.610
Hydrogen 10.7 10 5
Carbon 14.5 20.4 21.2
Nitrogen 2.2 4.2 4
Oxygen 71.2 64.5 43.5
Sodium 0.2 0.2 0.1
Phosphorus 0.4 0.1 8.1
Sulfur 0.2 0.2 0.3
Chlorine 0.3 0.3 –



















Fig. 2 – Number of neutrons on the surface of the W targetCalcium – – 17.6
Magnesium – – 0.2
.  Results  and  discussion
.1.  Optimal  spallation  target
s shown in Fig. 1, Ta and W have the highest neutron yield in
he mentioned materials; So W was selected as the spallation
arget because of having a higher melting point.
To determine the optimal dimension of the target, thick-
ess and radius of the cylindrical target were changed in the
ange of 1–6 cm and 2–14 cm,  respectively. Then, the neutrons
n the surface of the target were studied.
As expected, the number of produced neutrons in the
imension more  than the proton range in the target (based
n SRIM calculation, 3.27 cm for 230 MeV  in W)  is increased
radually. Simulation results from Fig. 2 indicate that increas-
ng the radius causes nuclear spallation reactions and (n, nx)
eactions by secondary particles themselves.12 Therefore, the
roduction of neutrons in the target will increase.
As seen in Fig. 2, no significant changes will occur in the
umber of neutrons in the dimensions greater than 7 cm in
adius and 3 cm in thickness, so they were selected as the
imensions of the spallation target.
The next step is to determine an optimum angle of the
arget relative to the incident proton beam direction. In thefor different radii.
optimum angle, most neutrons move close to the forward
direction at small angles. Because neutrons that move at
greater angles relative to the forward direction may change to
thermal neutrons by multiple collisions. The optimum angle
was calculated based on the simulation results of neutron
spectra at the entrance of the BSA for various target angles.
Therefore, the target was inclined 40 degrees relative to the
proton beam direction. Calculated neutron spectra at the
entrance of the BSA for four angles are given as samples in
Fig. 3.
4.2.  Beam  Shaping  Assembly  design
Table 5 shows the calculated figures of merit (FOM) for vari-
ous thicknesses of Iron moderator as an example. Iron with
15 cm thickness was selected due to its ability to decrease
the fast neutron dose (Fig. 4) (Dmax for both thicknesses are
approximately equal).In order to obtain a neutron beam suitable for BNCT, a ther-
mal  neutron filter is essential. Numerous simulations have
been carried out and the results show that Lithium Fluoride
648  reports of practical oncology and radiotherapy 2 4 ( 2 0 1 9 ) 644–653
Fig. 3 – Calculated neutron spectra at the entrance of the
BSA for various target angles relative to the proton beam
direction.




10 cm Fe 15 cm Fe 20 cm Fe
∅epi/∅fast 2.16E+1 2.73E+1 2.91E+1
∅epi/∅th 1.62E+2 1.38E+2 1.42E+2
∅epi [n/cm2s] 4.59E+6 3.94E + 6 3.31E+6
Ḋfast/∅epi [Gycm2/n] 9.16E-15 7.34E-15 8.87E-15
Ḋ /∅epi [Gycm2/n] 3.64E-14 3.38E-14 3.09E-14






∅epi [n/cm2s] 3.94E + 6 3.94E + 6
Ḋfast/∅epi [Gycm2/n] 7.34E-15 7.97E-15
Fig. 4 – Comparison of the fast neutron dose, for different
depths in the simulated head phantom for different
thicknesses of iron moderator.
Fig. 5 – Comparison of the fast neutron dose, the thermal
neutron dose and the gamma  dose for different depths in
achieve a better current-to-flux-ratio. Simulations for theseḊ /∅epi [Gycm2/n] 3.38E-14 3.35E-14
Jepi/∅epi 7.97E-1 7.94E-1
and Cadmium can improve the quality of the beam. Instead
of utilizing a thick layer of Lithium Fluoride as a thermal neu-
tron filter, Lithium Fluoride filters have been placed between
different layers of moderator materials. By doing so, epither-
mal  neutron flux increases and at the same time gamma rays
produced by BSA components decrease, especially the gamma
rays produced by Aluminum.
Gamma  neutron contamination should be limited by fil-
tering. Lead (Pb) and Bismuth (Bi) are used as gamma ray
filters. Both materials were tested and, even though Lead is
an excellent gamma ray filter, it increases both thermal neu-
tron dose and fast neutron dose (Fig. 5 and Table 6). As seen in
Figs. 5 and 6, total delivered dose to tumor and gamma  dose
using both filters are the same. Therefore, 0.5 cm of Bismuth
in optimized thickness was used as a gamma ray filter.It should be noted that a further increase in the thickness of
Bismuth filter, reduces the amount of gamma contaminationthe simulated head phantom for different gamma filters.
but decreases the epithermal neutron flux, which is obviously
undesirable.
Compounds like Bi, B4C and Li2CO3 can be used as a col-
limator to reflect neutrons back into the beam in order tothree collimators for different diameters and thicknesses have
been carried out and after obtaining their optimum values,
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Fig. 6 – Comparison of the total delivered dose between
tumor and normal tissues for different depths in the
simulated head phantom for different gamma  filters.
Table 7 – In-air measurements for different collimators.
Neutron beam
parameters
Bi  B4C Li2CO3
∅epi/∅fast 2.73E1 3.13E1 2.16E1
∅epi/∅th 1.38E2 1.32E2 1.34E2
∅epi [n/cm2s] 3.94E6 3.94E6 1.71E6
















Fig. 7 – Comparison of the fast neutron dose, the thermal
neutron dose and the gamma  dose for different depths in
the simulated head phantom for different collimators.
Fig. 8 – Comparison of the total delivered dose between
tumor and normal tissues for different depths in the
- The fast neutron and gamma contamination around theḊ /∅epi [Gycm /n] 3.38E-14 6.14E-14 7.66E-14
Jepi/∅epi 0.797 0.814 0.898
n-air neutron beam parameters were summarized in Table 7.
lthough Li2CO3 has a much better performance than other
ollimators, it decreases the neutron flux. The reduction of
pithermal neutron flux, if we use Li2CO3, is 43.5 percent com-
ared to the Bi collimator.
On the other hand, although, B4C has a better performance
han Bi (Table 7), it increases the thermal and fast neutron dose
Fig. 7).
In addition to in-air neutron beam parameters, in-phantom
easurements were calculated and they show that although
hermal and gamma neutron doses are significantly reduced
y Li2CO3 (Fig. 7), the dose which is delivered to tumor pro-
ided that we  use this, is not as effective as Bi and B4C (Fig. 8).
As a result, considering the above mentioned reasons, Bis-
uth was adopted as the best collimator.
Materials with high scattering cross section and hightomic mass (resulting in little energy loss), such as Lead or
ismuth, are used as a reflector.26 As in this study reflec-simulated head phantom for different collimators.
tor plays an additional role as a gamma shield, the following
points should be considered:BSA
- Designed neutron beam parameters
650  reports of practical oncology and radiotherapy 2 4 ( 2 0 1 9 ) 644–653
Fig. 9 – Comparison of fast neutron dose (A) and gamma  dose (B) around the BSA for different reflectors.







∅ [n/cm2s] (Per Proton) 6.07E-6 5.51E-6
Fig. 10 – Neutron energy distribution before and after
moderation corresponding to the optimal BSA.epi
Ḋfast/∅epi [Gycm2/n] 7.34E-15 1.95E-14
Ḋ /∅epi [Gycm2/n] 3.38E-14 3.07E-14
To determine the amount of fast neutron and gamma con-
tamination, some air spheres were placed around the BSA
(Fig. 11) and determined (Fig. 9). In addition, designed neutron
beam parameters are mentioned in Table 8. It can be seen that
Lead not only reduces fast neutron dose, but also fast neutron
and gamma contamination around the BSA. Therefore, Lead
was used as both the reflector and the gamma shield.
4.2.1.  Proposed  configuration  of  BNCT  irradiation  facility
The final configuration of the BSA design is illustrated in
Fig. 11. The proposed configuration has the following charac-
teristics:
- Target – Tungsten - 7 cm diameter and 3 cm thickness
- Moderator - 15 cm of Iron + 105 cm of Aluminum + 21.3 cm
Magnesium Fluoride (MgF2)
- Thermal neutron absorber – 0.1 cm of Cadmium + 3 layer of
Lithium Fluoride (3 × 0.1 cm)
- Reflector - Lead
- Collimator – 20 cm of Bismuth cone,
- Gamma  shield – 0.5 cm of Bismuth,
4.3.  Evaluation  the  proposed  facility
With the BSA configuration and beam current of 104 nA,
epithermal neutron flux of 3.94E + 6 [n/cm2] can be achieved.
The purity of neutron beam, the dose rate of fast neutron
to epithermal flux is 7.34E-15 [Gycm2/n] and the dose rate
of gamma to epithermal flux is 3.38E-14 [Gycm2/n], which is
comparable to most proposed or existing BNCT facilities. In
addition, in Fig. 10, a very good spectrum shifting towards the
epithermal energies can be observed: approximately, thermal
flux presents 0.66%, epithermal flux 95.8% and fast flux 3.54%
of the total neutron flux. The collimation of neutron beam is
quite satisfactory: 0.797.This moderation satisfies IAEA recommended values in the
beam exit window, except epithermal neutron flux. It would
lead to the unacceptable treatment time of 55 h for a 104 nA
proton beam current.
4.4.  Proposed  proton  beam  current
As mentioned in the previous section, the moderation would
lead to the unacceptable treatment time of 55 h for a 104 nA
proton beam. However, this unacceptably large treatment time
could be reduced potentially by increasing the beam intensity,
with a 5.75 A proton beam current; this way the treatment
time would shorten to 1 h. The therapeutic efficacy of neu-
tron beam for the proposed BNCT facility and beam current of
5.75 A was calculated through its in-phantom parameters as
shown in Fig. 12.
With this moderation and for around 47 min  irradiation
time, the maximum dose of 38.2 Gy-eq can be delivered to
tumor tissue at 1.4 cm from the phantom surface and the
equivalent tumor dose of 24.1 Gy-eq can be achieved at the
depth of 4.2 cm in the head phantom. This dose is lim-
ited by Brookhaven National Laboratory’s (BNL) clinical trial
protocol,23 which suggests that the local equivalent dose to the
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Fig. 11 – A cross-sectional view of the proposed BNCT facility modeling investigated in the present study.
Table 9 – In-phantom parameters evaluated for the proposed BSA and some other facilities.
Facility ADDR (cGy/min) TT (min) AD (cm) TD (cm) Tumor: normal tissue 10B
concentration (ppm)
Proposed facility (provided
that we use the beam
current of 5.75 A)
26.4  47:73 6.3 4 65:18
THORa  29 50 25 8.9 5.6 65:18
FiR 1 (Finland) 29 45 30 9 5.8 65:18
R2-0 (Sweden) 29 67 20 9.7 5.6 65:18
Kononov et al., 2004 30 100 12.5 9.1 – 65:18
FCB MITb 31 125 10 9.3 – 65:18






a Tsing Hua Open-Pool Reactor.
b MIT Fission Converter Beam (FCB).
ealthy tissue must not exceed 12.6 Gy. Thus, the treatment
ime will be limited by this value.27,28
With intention to evaluate the proposed facility (provided
hat we  use the beam current of 5.75 A), the calculated
ig. 12 – Depth dose rate profile along the beam axis as a functio
eam current of 5.75 A).in-phantom parameters were compared with some BSA con-
figurations of some previous published studies, which are
listed in Table 9. In addition to in-phantom parameters, the
calculated in-air neutron beam parameters of the proposed
n of depth in the head phantom (provided that we  use the
652  reports of practical oncology and radiotherapy 2 4 ( 2 0 1 9 ) 644–653
Table 10 – In-air neutron beam parameters evaluated for the proposed BSA and eight BNCT facilities worldwide.32









that we use the beam
current of 5.75 A)
0.015 0.218 0.806 0.0734
FiR 1 (Finland) 0.66 1.03 3.2 1.4
BMRRa 0.14 0.68 3.0 2.6
Petten (Netherlands) 0.04 0.32 4.7 6.4
KURRIb 0.03 0.35 3.2 7.2
MIT-FCB 0.97 4.29 15.8 0.9
RA-6 (Argentina) 0.28 0.68 4.3 7.9
WSU (USA) 0.09 0.27 1.1 2.6
JAERIc 18 0.81 2.3 1.8











b Kyoto University Research Reactor Institute.
c Japan Atomic Energy Research Institute.
facility and eight BNCT facilities worldwide are listed in
Table 10.
5.  Conclusions
In the present paper, the study is carried out using MCNPX2.6
code to evaluate the feasibility to use 230 MeV  proton cyclotron
in proton therapy centers as a spallation neutron source for
BNCT. In this simulation, high-energy spallation neutrons pro-
duced by 230 MeV  incident protons from Tungsten target were
moderated by a configuration of Iron, Aluminum and Magne-
sium Fluoride as the best moderator materials. In addition,
Lithium Fluoride and Cadmium as the thermal neutron fil-
ters and Bismuth as the gamma ray filter were used in the
proposed BSA. Results for 230 MeV  protons show that with
the proposed BSA, proton beam current of about 5.75 A is
required to reduce the treatment time to an acceptable region
of 47 min, which is accessible.
The biological dose evaluation in the simulated head phan-
tom shows that if we use the beam current of 5.75 A, the
maximum dose of 38.2 Gy-eq can be delivered to tumor tissue
at 1.4 cm from the phantom surface. In addition, it shows that
the neutron beam produced this way has lower AD compared
with other facilities. Hence, it is ineffective for the treatment
of deep-seated tumors in the brain.
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